Low dose haptenized tumor cell and tumor cell extract...

Details Low dose haptenized tumor cell and tumor cell extract... Low dose haptenized tumor cell and tumor cell extract...

2007-11-20

2007-11-20

Canella, Karen A. (Department: 1643)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Animal or plant cell

C424S573000, C514S110000

Reexamination Certificate

active

09776250

ABSTRACT:
This invention relates to compositions comprising haptenized tumor cells and extracts thereof, methods for preparing the compositions, vaccines comprising such haptenized tumor cells, and methods for treating cancer with such vaccines. In a specific embodiment, melanoma cells are haptenized with a dinitrophenyl group, and used for treatment of melanoma patients having metastatic disease. Preferably, patients are given a first vaccine dose containing haptenized cells to “prime” the immune system. Subsequently, patients are injected with an immunomodulatory compound such as cyclophosphamide. In a preferred embodiment, an appropriate time period after the “priming” vaccine dose, additional vaccine doses containing a mixture of haptenized cells and an adjuvant are administered. The described treatment plan is more effective for eliciting favorable anti-tumor immune responses.

REFERENCES:
patent: 5290551 (1994-03-01), Berd
patent: 5487982 (1996-01-01), Salter
patent: 5747269 (1998-05-01), Rammensee et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 6458369 (2002-10-01), Berd
patent: WO 92/00101 (1992-01-01), None
patent: WO 96/40173 (1996-12-01), None
patent: WO 98/14206 (1998-04-01), None
patent: WO 98/34641 (1998-08-01), None
patent: WO 99/40925 (1999-08-01), None
patent: WO 99/52546 (1999-10-01), None
patent: WO 99/56773 (1999-11-01), None
patent: WO 00/09140 (2000-02-01), None
patent: WO 00/29554 (2000-05-01), None
patent: WO 00/31542 (2000-06-01), None
patent: WO 00/38710 (2000-07-01), None
Martin et al, PNAS, 1971, vol. 68, pp. 469-472.
Berd et al, Ann NY Acad Sci, 1993, vol. 690, pp. 147-152.
Fujiwara et al, The Journal of Immunology, 1980, vol. 124, pp. 863-869.
Paul, Fundamental Immunology (text), 1993, pp. 1158-1159.
Yu and Resifo, Journal of Clinical Investigation, 2002, vol. 110, pp. 289-294.
Berd, Expert Review of Vaccines, 2004, vol. 3, pp. 521-527.
Berd, Seminars in Oncology, Dec. 1998, vol. 25, pp. 605-610.
Berd, Vaccine, 2001, vol. 19, pp. 2565-2570.
Sato et al, Clinical Immunology and Immunopathology, 1995, vol. 74, pp. 35-43.
Hanas and Leskowitz, Cellular Immunology, 1980, vol. 54, pp. 241-247.
St. Bernard, Encyclopaedia Britanica 2006. Encyclopaedia Britaannica Online. Jan. 19, 2006 <http://www.search.eb.com/eb/article-9064811>.
Berd et al. (Cancer Research, 1986, vol. 46, pp. 2572-2577).
U.S. Appl. No. 09/304,859, filed May 4, 1999, Berd.
Bach et al., J. Immunol., 1978;121(4):1460-1468.
Berd et al., Cancer Res 1991;51:2731.
Berd et al., Cancer Res 1986;46:2572.
Miller and Claman, J. Immunol 1976;117(5):1519.
Nahas and Leskowitz, Cellular Immunol., 1980;54:241-247.
Rötzschke et al., Nature 1990;348:252.
Sato, Cancer Immunol Immunotherapy 1996;43:174.
Sherman et al., J. Immunol., 1978;121:1432.
Weigle, J. Exp. Med., 1965;122:1049-1063.
D. Berd et al., U.S. Appl. No. 08/203,004, filed Feb. 28, 1994.
D. Berd et al., U.S. Appl. No. 08/479,016, filed Jun. 7, 1995.
David Berd, U.S. Appl. No. 08/899,905, filed Jul. 24, 1997.
David Berd, U.S. Appl. No. 08/942,794, filed Oct. 2, 1997.
D. Berd et al., U.S. Appl. No. 09/447,897, filed Nov. 23, 1999.
Sato et al., Cancer Invest., 1997;15:98-105.
Kim et al., Eur. J. Immunol., 1992;22:775-782.
Sherman et al., J. Immunol., 1978;121:1432-1436.
Grabbe et al., Immunol.Today, 1995;16:117-121.
Siena et al., Exp. Hematol., 1995;23:1463-1471.
Sahasrabudhe et al., J. Immunol., 1993;151:6302-6310.
Shamamian et al., Cancer Immunol. Immunother., 1994;39:73-83.
Cox et al., Science, 1994:264:716-719.
Peoples et al., J. Immunol., 1993;151:5481-5491.
Jerome et al., Cancer Res., 1991;51:2908-2916.
Morioka et al., J. Immunol., 1994;153:5650-5658.
Burrows et al., J. Neurosci. Res. 1997;49:107-116.
Gavin et al., Eur. J. Immunol., 1994;24:2124-2133.
Edman et al., Eur. J. Bio-chem., 1967;1:80-91.
Kempkes et al., J. Immunol., 1991;147:2467-2473.
Jang et al., Eur. J. Immunol., 1991;21:1303-1310.
Pistoor et al., J. Invest. Dermatol., 1995;105:92-95.
Nalefski and Rao, J. Immunol., 1993;150:3806-3816.
Carlsson, et al., Biochem J., 1978;173:723-737.
Miller et al., J. Immunol., 1976;117:191-196.
Brown, “Albumin structure, function and uses”, Rosenoer, V.M. et al. (eds.), Pergamon Press:Oxford, pp. 27-51, 1977.
Weitkamp, L.R., et al., Ann. Hum. Genet., 1973;37:219-226.
Hood et al., “Tolerance and the Regulation of Immunity”, Second Edition, 1984, Benjamin-Cummings: Menlo Park, CA, pp. 366-401.
McCune et al., Cancer, 1979;43:1619-1623.
Pulaski et al., Cancer Res., 1998;58:1486-1493.
Berd et al., J. Clin. Oncol., 1997;15:2359-2370.
Rennke et al., Kidney International, 1994;45:1044-1056.
Heppner et al., Cancer Res. 1978;38:3758-3763.
Miller et al., Cancer Res., 1981;41:3863-3867.
Miller, Invasion Metastasis, 1981;1:220-226.

Affiliated with

Also associated with

Rating

Low dose haptenized tumor cell and tumor cell extract... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Low dose haptenized tumor cell and tumor cell extract..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low dose haptenized tumor cell and tumor cell extract... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3810309